Pass PEGAPCRSA80V1_2019 exam with 100 percent marks with Actual Questions

We have legitimate and state-of-the-art PEGAPCRSA80V1_2019 Exam questions that are made up of PEGAPCRSA80V1_2019 bootcamp, tested and verified by our certified team. killexams.com gives the most specific and most recent exam practice questions which almost involves all test themes. With the database of our PEGAPCRSA80V1_2019 test prep, you do not have to risk your chance on reading PEGAPCRSA80V1_2019 textbooks but surely need 24 hrs to get ready for the real PEGAPCRSA80V1_2019 exam.

Exam Code: PEGAPCRSA80V1_2019 Practice exam 2022 by Killexams.com team
PEGAPCRSA80V1_2019 Pega Certified Robotics System Architect 80V1 2019

60 Questions
1 hr 30 mins
Passing Score: 65%

Exam syllabus (% of exam)
Project Management (5%)
Identify importance of Solution Design Documents
Identify importance of Solution Architecture Documents
Recognize solution structure based on project documentation
Define types of projects created for a robotic solution
Recognize proper naming conventions of solutions and projects
System Integration (8%)
Recognize and configure Pega Robot Studio adapter types
Identify adapter properties and values of Windows adapters
Identify adapter properties and values for Web adapters
Identify adapter properties/values for Universal Web adapters
Modify the properties of an object
Interrogation (13%)
Identify elements created and used during interrogation
Recognize the difference between Web and Windows interrogation
Interrogate Web applications - standard, Select Element methods
Identify the purpose of Global web pages during interrogation
Know why and when to use Select Element to interrogate
Describe the Create Control method of interrogating
Modify match rules for windows and web adapters
Modify Universal web adapter match rules
Identify match rule best practices and common issues
Identify working panes in the Adapter Match rules tab
Add and edit match rules for an interrogated control
Debugging and Diagnostics (20%)
Evaluate data values in an automation during debugging
Update diagnostics settings
Add a diagnostic log component to an automation
Dissect a log file
Use the Automation playback feature
Clear a log file
Automations (33%)
Describe relationship between Object Explorer and automations
Implement the Object Explorer in automation development
Create an automation
Implement Message dialogs
Identify types of automation links
Create an automation procedure using Label/Jump To Components
Application and setting of UseKeys property
Implement the RaiseEvent method within an automation
Identify uses and extraction of data proxies
Create a windows form for use in a project
Describe Toolbox components: Variables, Excel file connector
Identify Decision Blocks, Comparisons, and Expressions
Describe use of utilities for Strings, Dates, and Files
Describe use of Wait logic
Differentiate use and parameters for Automation looping
Describe and implement of Assisted Sign-On
Describe and implement Start My Day, Message Manifest
Interaction Framework (13%)
Explain and modify the interaction.xml file
Configure and use the Interaction Manager component
Explain and create a project-to-project reference
Define the structure of context values
Implement an activity component
Deployment (8%)
Create Project configuration files
Use of Project deployment properties
Create a deployment package

Pega Certified Robotics System Architect 80V1 2019
Pegasystems Certified answers
Killexams : Pegasystems Certified answers - BingNews https://killexams.com/pass4sure/exam-detail/PEGAPCRSA80V1_2019 Search results Killexams : Pegasystems Certified answers - BingNews https://killexams.com/pass4sure/exam-detail/PEGAPCRSA80V1_2019 https://killexams.com/exam_list/Pegasystems Killexams : Pega University, TalentSprint help 10,000 engineering students get jobs

Pega University programme, jointly offered by Pegasystems and edtech company TalentSprint, said it has so far helped about 10,000 engineering students get jobs in the last seven years. The two-semester programme, which started with two colleges six years ago, now covers 18 colleges in different states in the country, equipping students with skills required to work on the Pega platform.

The programme, offered to engineering college students in their third year, will help students work on low-code technologies to Boost their employability. The programme involves over 300 hours of hands-on experiential learning offered by qualified instructors.

“The programme has been effective in creating certified, ready-to-deploy young software engineers,” Deepak Visweswaraiah, Vice-President (Platform Engineering), and Site Managing Director, Pegasystems, India, said here in a statement on Monday.

“We have partnered with more than 24 global blue-chip companies to conduct exclusive placement drives, resulting in a consistent placement rate of over 80 per cent. By the end of the financial year, about 10,000 students would have benefited from this programme,” he said.

The company targets to get placements to 1,600 students in 2023. Santanu Paul, CEO and MD, TalentSprint, said that the programme holds a 95 per cent certification rate.

Mon, 28 Nov 2022 09:16:00 -0600 en text/html https://bloncampus.thehindubusinessline.com/engineering/pega-university-talentsprint-help-10000-engineering-students-get-jobs/article66194707.ece?_escaped_fragment_=
Killexams : Addressing the Knowledge Gap in Biologics & Biosimilars: Is a Board Certified Biologics and Biosimilars Program the Answer?

Life sciences professionals will need to keep up with market demand for biologics and biosimilars.

The Accreditation Council for Medical Affairs (ACMA) will launch the Board-Certified Biologics and Biosimilars Specialist Program (BCBBS), the first accredited program specializing in biologics and biosimilars, in December 2022.

According to the IQVIA Institute for Human Data Science, biologics, medications derived from living organisms, have emerged as one of the fastest growing markets.4 In the United States, biologics account for 43% of all drug spending.3 Increasing demand for vaccines and targeted therapies, along with advances in drug development through artificial intelligence, are driving growth in the global biologics industry.

As the biologics market rapidly expands, professionals will need skills aligned with market demands to ensure the adoption of biologics and biosimilars. The adoption of biosimilars plays a critical role in reducing the overall cost of drug prices, especially in the United States. Biosimilars are "highly similar" to originator biologics yet are typically 30% less expensive.3 The BCBBS program offered by the ACMA will enable healthcare and life sciences professionals to gain insight into biologics and biosimilars beyond clinical guidelines. Understanding the regulatory, reimbursement, and economic implications of biologics enhances life science professionals' ability to navigate a rapidly evolving market.BCBBS will also provide 10 continuing education (CE/CME) credits to U.S licensed physicians and pharmacists.

The ACMA and the U.S. Food and Drug Administration (FDA) recognize the importance of preparing life sciences professionals for the expanding biologics market through education. The ACMA created the BCBBS program to educate all life sciences professionals (e.g., pharmacists, prescribers, PhDs, Industry/MSLs, etc.). The BCBBS program ensures life sciences professionals can navigate the complex regulatory and reimbursement landscape of biologics, establishes experts for healthcare provider (HCP) education, and sets industry standards for managing biologics and biosimilars.

Aligning Skills Training With Market Trends

Regulatory and reimbursement landscapes have become complex as the biologics market has evolved. The BCBBS program provides practical skills to overcome reimbursement obstacles and ensure patients can access affordable medications. During the program, participants learn how to choose life-saving therapies strategically for patients, navigate Medicare Part B and Medicare Part D reimbursement processes, determine eligibility for pass-through status, and evaluate the cost-effectiveness of comparable therapies.

As the biologics market has grown in recent years, medical affairs teams have become increasingly involved in optimizing patient access and communicating the value of new therapies, including biologics and biosimilars, to HCPs and other stakeholders.1 Optimizing patient outcomes requires a team of knowledgeable, highly skilled professionals who can facilitate biologics development, commercialization, and communication. Creating effective medical affairs teams for the future starts with cultivating the essential knowledge and skills to adapt to evolving biologics industry trends. The BCBBS program offers the education required to empower medical affairs teams and enable them to succeed.

Establishing Experts to Enhance Provider Education

Medical affairs will increasingly play a vital role in educating HCPs about biosimilars, including their potential to reduce prescription drug costs and enhance health equity. According to IQVIA’s Biosimilars in the United States 2020–2024 report, biosimilars have the potential to reduce prescription drug costs by $100 billion over the next five years.3 However, biosimilar adoption faces many barriers, including provider hesitation.5

While biosimilars can Boost patient care, a lack of provider education is a significant obstacle.5 The FDA approved the first biosimilar in 2015, making biosimilars a relatively new class of drugs. When new therapies are introduced, providers often question their safety and efficacy.2

Developing medical affairs teams capable of communicating biosimilars' value to HCPs and other stakeholders is essential to improving biosimilar adoption. The United States passed the Advancing Education on Biosimilars Act in April 2021 in recognition of the need to educate HCPs about biosimilars. The law requires the FDA to maintain an educational website for HCPs and patients to increase awareness of biosimilars' benefits.

With biologics expanding into new therapeutic areas, many certified are prescribing biologics for the first time creating demand for effective HCP education.2 The Pharmaceutical Research and Manufacturers of America (PhRMA) trade group also acknowledges the need for additional biosimilar education and experts. According to the group, “we need to encourage continued focus on increasing provider and patient education to maximize the benefits…this effort should include the development and dissemination of evidence-based materials on the full range of treatment options, including biosimilars, to further support appropriate biosimilar adoption.” The BCBBS program provides this education and establishes experts in biosimilars to enhance their adoption.

Setting Industry Standards

Since 2015, the ACMA has been setting industry standards for the life sciences industry. Over the years, the ACMA has educated and trained thousands of life science professionals. Along with education, students receive mentorship and earn continuing education hours when completing certifications. The ACMA recognizes the importance of biologics education in preparing future industry leaders.

According to William Soliman, Ph.D., BCMAS, ACMA Founder and CEO, “the ACMA believes that establishing a standard of excellence for the biologics and biosimilars arena will be key as the life sciences industry navigates several obstacles regarding the adoption of biosimilars such as clinical confidence and patient insurance and prior authorization issues.”

The BCBBS program enables professionals to develop skills for the future through a practical case-based approach, expert-developed content, and a flexible learning environment. To learn more about ACMA’s BCBBS program, visit the following resources.

Learn more about the ACMA's Board Certified Biologics and Biosimilars Specialist Program here. Register for an upcoming webinar on the syllabu of Biologics & Biosimilars Interchangeability, here.

References:

  1. Bedenkov A, Rajadhyaksha V, Beekman M, et al. Developing medical affairs leaders who create the future. Pharmaceut Med. 2020;34(5):301-307. doi:10.1007/s40290-020-00351-y
  2. Cardinal Health. 2022 Cardinal Health Biosimilars Report: The U.S. Journey and Path Ahead.; 2022.https://www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/biosimilars/biosimilars-report.html
  3. IQVIA Institute for Human Data Science. Biosimilars in the United States 2020–2024. 2020. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024
  4. IQVIA Institute for Human Data Science. Disruption and maturity: The next phase of biologics. 2017. https://www.iqvia.com/-/media/iqvia/pdfs/nemea/uk/disruption_and_maturity_the_next_phase_of_biologics.pdf
  5. Oskouei ST, Kusmierczyk AR. Biosimilar Uptake: The Importance of Healthcare Provider Education. Pharmaceut Med. 2021;35(4):215-224. doi:10.1007/s40290-021-00396-7
Fri, 04 Nov 2022 19:06:00 -0500 en text/html https://www.pharmexec.com/view/addressing-knowledge-gap-biologics-biosimilars-board-certified-biologics-biosimilars-program-answer
Killexams : Whether 14th Amendment applies to Trump depends on 3 eligibility questions

A House Democrat says the 14th Amendment bars Trump from becoming president again, if elected. But law experts say there are three key points to answer first.

The 14th Amendment was trending on Twitter following Donald Trump’s announcement that he would be running for president again in 2024, with people claiming the constitutional amendment could keep the former president from serving in office again. 

House Democrat Rep. David Cicilline (D-R.I.) also sent a letter to colleagues asking them to join him in sponsoring legislation that disqualifies Trump from the presidency because of the 14th Amendment. The letter was sent in full to VERIFY by Cicilline’s office.

Cicilline referenced Section 3 of the 14th Amendment, otherwise known as the “Insurrection Clause.” Cicilline says Trump “engaged in insurrection on Jan. 6 with the intention of overturning the lawful 2020 election results.” His legislation, he wrote, “would prevent Trump from holding public office again under the Fourteenth Amendment.” 

VERIFY viewer David emailed us to ask if the 14th Amendment would keep Trump from office.

THE QUESTION

Does the insurrection clause in the 14th Amendment apply to Donald Trump?

THE SOURCES

THE ANSWER

Section 3 of the 14th Amendment dates back to the Civil War. The intention was to prevent the president from allowing former leaders of the Confederacy, who engaged in rebellion against the U.S., from holding office after they were granted presidential pardons.  

“No person shall be a Senator or Representative in Congress, or elector of President and Vice-President, or hold any office, civil or military, under the United States, or under any State, who, having previously taken an oath, as a member of Congress, or as an officer of the United States, or as a member of any State legislature, or as an executive or judicial officer of any State, to support the Constitution of the United States, shall have engaged in insurrection or rebellion against the same, or given aid or comfort to the enemies thereof. But Congress may, by a vote of two-thirds of each House, remove such disability.”

In plain language, this generally means that someone who “engaged in insurrection or rebellion” can’t hold certain public offices. 

But several legal experts argue this probably doesn’t apply to Trump. They point to three eligibility questions: 

  1. Did Trump’s conduct amount to engaging in an insurrection?
  2. Who does this apply to in government?
  3. Is the president considered “an officer of the United States”?

We’ll go through the answers to these questions individually. 

Did Trump’s conduct amount to engaging in an insurrection?

Robert S. Peck, founder and president of the Center for Constitutional Litigation, told VERIFY in an email the issue “becomes whether Donald Trump engaged in the forbidden conduct.” It would be up to Congress to determine if he is guilty of participating in an insurrection.

If Congress did find Trump guilty of engaging in an insurrection, that finding could ultimately result in a disqualification from holding office. But constitutional law experts say Trump would likely file a lawsuit to challenge the validity of those accusations.

“At issue in the lawsuit would be whether his actions qualified as engaging in insurrection or rebellion or giving aid or comfort to enemies of the Constitution. Because we have no precedent for how a court would approach that issue, one would expect that the evidence gathered by the January 6th Committee and by the Justice Department would be aired in court with judges deciding whether it is sufficient to invoke the Fourteenth Amendment,” Peck said.

This is the first factor to consider – can it be proven that Trump actually did engage in an insurrection or rebellion? As of Nov. 16, he has not been charged or convicted in connection to the Jan. 6 insurrection.

Who does the section apply to in government?

Doron Kalir, clinical professor of law at Cleveland-Marshall College of Law,  told VERIFY as presently written and as he interprets it, the highest office this section would apply to is a senator. Kalir said the section says the rules apply to people in the following positions: 

  • a senator or representative in Congress, or  an elector of president and vice president 
  • an officer in any civil or military position 
  • A person who holds any office, civilian or military 
  • A person who has taken an oath, as a member of Congress, or as an officer of the United States, or as a member of any State legislature

Kalir says as it’s interpreted, the president does not hold an official station within the U.S. military despite the title of “commander in chief” – that is not a rank within the U.S. military but gives the president authority to preside over some military operations. The president is also not considered a civilian. 

“So there is very strong support to the hypothesis that Donald Trump is not included in the list of persons on whom this will apply,” Kalir said. 

Is the president considered “an officer of the United States”?

Though “president” is never specified in the section, “officers of the United States” are. 

“The question is whether the former president may be considered an officer of the United States for purposes of Section 3, Article 14. There is no certified answer by the United States Supreme Court for this question,” Kalir told VERIFY. 

But, Kalir said the Supreme Court has spoken on this syllabu before. In 2010, Chief Justice John Roberts issued an opinion in the case of the Free Enterprise Fund v. Public Company Accounting Oversight Board, which spoke directly to whether the president is considered an officer.

Roberts said, “The people do not vote for the ‘officers of the United States.’ Rather, ‘officers of the United States’ are appointed exclusively pursuant to Article II, Section 2 procedures. It follows that the President, who is an elected official, is not an ‘officer of the United States.’”

In other words, only people in appointed positions are considered officers, Roberts said. Since the president is not appointed, he wouldn’t be considered an officer, according to the opinion. 

It's important to note that there is no precedent as to whether this applies to the president or a former president.  So this would need to be argued in court.

Kalir said all of these eligibility requirements would likely be answered well ahead of the November 2024 elections if Trump ends up on the ballot. 

“I can assure you that every federal court that would look at it from a district court level through the Court of Appeals, and all the way up to the United States Supreme Court … In 2024, there will be clarity as to the constitutional eligibility of Donald Trump for running,” Kalir said. “There will be no doubt by the time 2024 is upon us - What is the eligibility according to the Constitution?”

The VERIFY team works to separate fact from fiction so that you can understand what is true and false. Please consider subscribing to our daily newsletter, text alerts and our YouTube channel. You can also follow us on Snapchat, Twitter, Instagram, Facebook and TikTok. Learn More »

Follow Us

Want something VERIFIED?

Text: 202-410-8808

Thu, 17 Nov 2022 04:39:00 -0600 en-US text/html https://www.13newsnow.com/article/news/verify/donald-trump/whether-14th-amendment-applies-to-trump-depends-on-3-eligibility-questions/536-5c0a3f9a-c3d1-4315-846f-7af6e0fd8a30
PEGAPCRSA80V1_2019 exam dump and training guide direct download
Training Exams List